Testing Archives - COVIDRheum

Homepage Testing

Testing

COVID Rheum Patient Registry Form

March 23, 2020

Coming Soon COVID Rheum Patient Registry Form

COVID-19, burnout may lead to nursing workforce shortage ‘in years to come’

ORLANDO — Burnout and the personal impacts of the COVID-19 pandemic among health care providers may lead to a long-term nursing shortage nationwide, according to a presenter at the 2022 Rheumatology Nurses Society Annual Conference.“The combination of burnout and the pandemic could put the United States in a position of a nursing workforce shortage in years to come,” Carrie Beach, BSN, RN-BC, president of RNS and staff rheumatology nurse at the Columbus Arthritis Center, in Columbus, Ohio, told attendees.To combat these effects, Beach stressed that self-care and positive
Different types of arthritis ‘present very differently’ in synovium, synovial fluid

ORLANDO — Understanding the nature and role of the synovium and synovial fluid is critical to managing various types of arthritis, according to a presenter at the 2022 Rheumatology Nurses Society Annual Conference.“We are often draining joints, but what can you tell from the synovial fluid you have collected?” Adam J. Brown, MD, associate program director of the Cleveland Clinic, asked attendees.Brown’s talk covered the makeup of synovial fluid, how it works and what clinicians should be looking for in a fluid analysis. However, he stressed that the answers to many
One-third of patients with rheumatoid arthritis-associated ILD experience acute exacerbation

The incidence of acute exacerbation was nearly one-third in patients with rheumatoid arthritis-associated interstitial lung disease, researchers reported in Chest.Ever smoking, lower lung function and exercise capacity were identified as risk factors for acute exacerbation in this patient population.“Determining the incidence, risk factors and effects of acute exacerbation on the prognosis in patients with rheumatoid arthritis-associated ILD remains challenging,” Byoung Soo Kwon, MD, from the division of pulmonary and critical care medicine at Seoul National University Bundang
FDA approves ustekinumab for pediatric psoriatic arthritis

The FDA has approved ustekinumab for the treatment of children aged 6 years and older with active psoriatic arthritis, according to a Janssen press release.“We know active pediatric psoriatic arthritis is a challenging inflammatory disease given its rarity and that symptoms, such as swollen joints and skin lesions, can vary significantly in presentation and severity,” Terence Rooney, MD, PhD, vice president of Janssen Research & Development’s Rheumatology and Maternal Fetal Disease Area, said in the release. “With this pediatric approval of Stelara, we’re